Navigation Links
Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem
Date:3/8/2012

ginal candidiasis (RVVC) is a common and moderate-to-severe chronic condition, which occurs in 7% of all adult women. To date, no study has been conducted to properly assess patients' QoL using validated questionnaires. The disease is characterized by the frequent recurrence of acute inflammations of the vagina and vulva, caused by an overgrowth of Candida albicans, and is defined as four or more acute episodes per year. Clinical symptoms cause extreme discomfort and pain and the quality of life (QoL) of patients is strongly impacted, both physically and psychologically.

Pevion has mandated a survey among more than 600 RVVC patients in the US and in the five largest European countries in order to assess the global QoL in a quantitative manner employing the validated EQ-5D and SF-36 scoring systems. The survey data show that the QoL is substantially diminished not only during an acute inflammatory episode, but also in the periods between recurrences. This reflects the maintained discomfort and stress in between acute episodes, which is accompanied by anxiety and depression in a large proportion of patients. The characteristics of a chronic disease are clearly given and the overall utility scores are significantly lower than the general population's reference value, and this, under the current standard of care. Moreover, the results show strong consistency between the six countries.

The survey revealed that there is a strong impact on patients' usual daily activities and work. A significant loss of productivity has been recorded, which represents a valuable economic damage.

The survey also investigated current treatment patterns among RVVC patients. In those patients who followed a long-term maintenance therapy with antifungal drugs, as recommended by guidelines from several medical societies, relapse occurred in two thirds of cases already within a few months. This low benefit explains why less than half of the patients actually receive su
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
2. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
3. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
4. Pevions Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 20, 2015 ... addition of the "Global Post-traumatic Stress Disorder Therapeutics ... The global PTSD therapeutics market to grow at a ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:7/28/2015)... July 28, 2015 According to a ... Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, ... - Forecast to 2020", published by MarketsandMarkets, the European Injectable ... 2020 from $114.7 Billion in 2015, growing at a CAGR ... 230 market data T ables ...
(Date:7/27/2015)... SEATTLE , July 28, 2015 CTI ... it plans to report its second quarter 2015 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
(Date:7/28/2015)... ... July 28, 2015 , ... According to WFTV on ... the lead among heroin toxicity cases. According to recent statistic Orlando suffers at least ... known as a hub of heroin, and law enforcement officials are struggling to keep ...
(Date:7/28/2015)... ... 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) (“the Company”) today ... time and depending on market conditions, to repurchase shares of its outstanding common ... made in open market or privately negotiated transactions in compliance with Securities and ...
(Date:7/28/2015)... ... , ... Every summer, the public is reminded to leave the Fourth of ... their own neighborhoods. Unfortunately, according to a recent report issued by the U.S. Consumer ... " Eye Injuries Caused by Fireworks Doubled in Last 3 Years ," the number ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... Water line has won the 2015 NCW Eco-Excellence Award for the Nutrition Beverage ... and pet lifestyle industries and elevate companies that stand out for their social ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine has adopted a new ... more service offerings, updated treatment techniques, and additional state-of-the art online resources for patients. ... invasive surgical treatment of brain and spine conditions. , “Adding the word ‘pain’ ...
Breaking Medicine News(10 mins):Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
... HealthDay Reporter , MONDAY, Jan. 23 (HealthDay News) -- Since ... questioned the safety of medical procedures used to terminate pregnancy. ... abortion is safer than carrying a baby to term. ... delivery is 8.8 deaths per 100,000, while the risk of ...
... world media, researchers, academics including several from Simon Fraser ... the Vancouver Convention Centre Feb. 16-20. , Simon Fraser University,s ... of a bell announcing the 2012 AAAS (American Association ... Aquarium yesterday. , "The AAAS conference is a must for ...
... MRI helps surgeons make more informed decisions about nerve-sparing ... new study published online in the journal Radiology ... most common cancer diagnosed in American men, according to ... prostatectomy, or removal of the prostate, is a common ...
... Jan. 24, 2012) For men diagnosed ... drug dutasteride ("Avodart") delays disease progression and initiating active ... a three-year international clinical trial led by Dr. Neil ... Network (UHN). The findings are published online ...
... Wakeling is adding to the arsenal of increasingly sophisticated ... viewing muscle activation details that have never been seen ... movement in people and animals, Wakeling has developed a ... proprietary data-processing software to scan and capture 3D maps ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Jan. ... be bad for you, a new study finds that parts of ... with others. It,s not clear how this effect of stress ... system -- which cause inflammation in the body -- have been ...
Cached Medicine News:Health News:Abortion Safer for Women Than Childbirth, Study Claims 2Health News:Abortion Safer for Women Than Childbirth, Study Claims 3Health News:SFU hits hot buttons at 2012 AAAS conference 2Health News:SFU hits hot buttons at 2012 AAAS conference 3Health News:Preoperative MRI may reduce risk of nerve damage in prostate cancer surgeries 2Health News:Prostate cancer study proves drug delays disease progression 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3
... Intelli-Storeroom™ was developed to create physically secured ... and exits are converted to RFID portals. ... readers and antennas by VerdaSee's Field Engineering ... to assets that are to be tracked. ...
... Mobile Aspects provides hospitals ... products to track all their ... Our RFID systems remove all ... items and people accurately. iRIS, ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
... AgileTrac Surgical Services is a Web-based ... to track, manage, and measure patient flow ... process, from admission to discharge. AgileTrac collects ... of care delays your patient might experience. ...
Medicine Products: